|
|
|
|
| Advertisement |
 |
|
|
| Top Story |
|
|
Is the Hatch-Waxman System Broken? |
| The 1984 Hatch-Waxman (HW) Act was intended to be a fair compromise between research-based pharma and the generic companies. Traci Medford-Roscow and Peter C. Richardson write the Act has more than achieved its goals of providing lower-priced generic drugs to the American consumer, but that the goal of incentivizing research and new drug discovery has fallen short ... /Read more/ |
|
|
| Regulatory |
|
|
| Sales & Marketing |
|
Reaching the Unreachables
|
|
The modern sales and marketing approach has evolved to allow agile commercial organizations to orchestrate delivery of on-demand resources to once unreachable physicians, writes Todd Greenwood ... /Read more/ |
|
|
|
| Industry update |
| //Idera Pharmaceuticals (Cambridge, MA, and Exton, PA) announced that Maxine Gowen, Ph.D., joined its Board of Directors, effective January 4, 2016.//Advaxis (Princeton, NJ) has established a Scientific Advisory Board. The Board's founding members are Antoni Ribas, M.D., Ph.D., Jedd Wolchok, M.D., Ph.D., Nancy Freitag, Ph.D., and Marc Lecuit, M.D., Ph.D.//Global Blood Therapeutics (South San Francisco, CA) appointed Scott Morrison to its Board of Directors.//AMAG Pharmaceuticals (Waltham, MA) appointed Nicholas (Nik) Grund as Executive Vice president and Chief Commercial Officer.//Achillion Pharmaceuticals (New Haven, CT) named Joel Barrish, Ph.D., as Chief Scientific Officer (CSO) and Executive Vice President, effective January 4, 2016.// |
|
|
|
|
|
|
|
|
